Literature DB >> 19843050

Panitumumab.

Eline A Dubois, Adam F Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19843050      PMCID： PMC2780272          DOI： 10.1111/j.1365-2125.2009.03492.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

1.  Panitumumab.

Authors:  Leonard Saltz; Chris Easley; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

Review 2.  Comparing antibody and small-molecule therapies for cancer.

Authors:  Kohzoh Imai; Akinori Takaoka
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716
  2 in total
  10 in total

1.  Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging.

Authors:  Siyuan Ren; Xiang Sun; Haixing Wang; Trung Hai Nguyen; Negar Sadeghipour; Xiaochun Xu; Chi Soo Kang; Yujie Liu; Hua Xu; Ningjie Wu; Yanda Chen; Kenneth Tichauer; David D L Minh; Hyun-Soon Chong
Journal:  ChemMedChem       Date:  2018-11-26       Impact factor: 3.466

Review 2.  Monoclonal antibodies for the treatment of cancer.

Authors:  Casey W Shuptrine; Rishi Surana; Louis M Weiner
Journal:  Semin Cancer Biol       Date:  2012-01-08       Impact factor: 15.707

Review 3.  Targeted therapies in gastric cancer treatment: where we are and where we are going.

Authors:  Gianluca Tomasello; Michele Ghidini; Wanda Liguigli; Margherita Ratti; Laura Toppo; Rodolfo Passalacqua
Journal:  Invest New Drugs       Date:  2016-02-12       Impact factor: 3.850

4.  Panitumumab (vectibix).

Authors:  J J Gemmete; S K Mukherji
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

5.  A homogeneous bioluminescent immunoassay for parallel characterization of binding between a panel of antibodies and a family of Fcγ receptors.

Authors:  Nidhi Nath; Becky Godat; Rod Flemming; Marjeta Urh
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

6.  IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.

Authors:  Josef Singer; Erika Jensen-Jarolim
Journal:  J Carcinog Mutagen       Date:  2014-05-31

7.  Cell death signaling and anticancer therapy.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Erika Vacchelli; Guido Kroemer
Journal:  Front Oncol       Date:  2011-05-03       Impact factor: 6.244

Review 8.  Emerging functions of the EGFR in cancer.

Authors:  Sara Sigismund; Daniele Avanzato; Letizia Lanzetti
Journal:  Mol Oncol       Date:  2017-11-27       Impact factor: 6.603

Review 9.  New therapeutic options opened by the molecular classification of gastric cancer.

Authors:  Mihaela Chivu-Economescu; Lilia Matei; Laura G Necula; Denisa L Dragu; Coralia Bleotu; Carmen C Diaconu
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

10.  BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.

Authors:  Evelina Miele; Luana Abballe; Gian Paolo Spinelli; Zein Mersini Besharat; Giuseppina Catanzaro; Martina Chiacchiarini; Alessandra Vacca; Agnese Po; Carlo Capalbo; Elisabetta Ferretti
Journal:  BMC Cancer       Date:  2020-02-17       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.